Clinical Trial Update: Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and efficacy of oral belumosudil in chronic graft-versus-host disease in diverse participants has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Belumosudil (belumosudil)

Snippet

Sponsor: Kadmon, a Sanofi Company | Conditions: Chronic Graft Versus Host Disease | Phase 2 | Status: WITHDRAWN